Navigation Links
Hard to Treat Diseases, Inc. (HTDS) Reports on New Uses For Ribavirin
Date:5/20/2009

BioChem.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc. 's control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurr
'/>"/>

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
5. Free distribution of insecticide-treated mosquito nets can save lives
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. Broad-based group of physicians calls for improvement in stroke treatment
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
10. Non-medicinal treatment touted for pre-schoolers with ADHD
11. Nonmedicinal treatment touted for preschoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... STOCKHOLM, SWEDEN (PRWEB) August 21, 2014 ... today that this year's conference will focus on ... be expected for research, innovation and commercialization. , ... successful ventures, SALSS combines the worlds' of business ... to a widely recognized Summit, gathering a diverse ...
(Date:8/21/2014)... News) -- In a new review of seafood safety, ... tuna due to concerns about mercury exposure. "We,re ... to shrimp as the most commonly eaten seafood in ... all tuna," Jean Halloran, director of food policy initiatives ... said in a news release from the group. ...
(Date:8/21/2014)... (HealthDay News) -- Using two types of polio vaccines ... may boost efforts to eradicate polio, a new study ... India found that giving the Salk inactivated poliovirus vaccine ... Sabin live-attenuated oral poliovirus vaccine (OPV) appeared to improve ... The findings, reported in the Aug. 22 issue of ...
(Date:8/21/2014)... 2014 The Onder Law Firm, nationally-renowned ... law, announces the launch of a new Morcellator Cancer ... morcellator surgery lawsuits for cancer claims, including ... warning and the July 2014 morcellator recall. , ... 2014 FDA warning on morcellator surgery and cancer, federal ...
(Date:8/21/2014)... 2014. Researchers have published a study examining racial ... with motor complete spinal cord injury (SCI). The ... discharge and follow-up among patients with motor complete ... August 2 by the Archives of Physical ... small but significant differences in self-care and mobility ...
Breaking Medicine News(10 mins):Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2
... Organizations, Advocates, Government Agencies, and Scientists from Academic Institutions ... ... 13 Leadership and senior staff of,twenty- seven breast ... along with experts from government agencies, scientists,from academic institutions ...
... Society of America (GSA) has chosen W. Andrew Achenbaum ... of the Donald P. Kent Award. This distinguished honor ... exemplifies the highest standards for professional leadership in gerontology ... larger society. , The award presentation will take ...
... has chosen Nancy L. Pedersen of Sweden,s Karolinska Institutet ... Contribution to Gerontology. This prize is given annually to ... a new synthesis and perspective or have yielded original ... the literature. , The award presentation will take place ...
... operated on, or the wrong transplant, study found , , TUESDAY, ... in eye surgery, say U.S. researchers who analyzed 106 cases ... the wrong site or using wrong procedure. , The ... College in New York found: , The most common ...
... Nov. 13 Green Earth Waterless Carwash, the,only Los ... products and auto detailing services, today announced an agreement,with ... month as part of,the hospital,s employee appreciation program. An ... to the hospital. "We originally signed on for ...
... - Seattle & King County and RediClinic, offers Seattle-area residents a, convenient opportunity to get ... themselves and the many lives they touch, - Vaccination ... ... between mid ...
Cached Medicine News:Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 2Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 3Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 4Health News:Eye Surgery Errors Rare But Serious 2Health News:Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 3Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 4Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 5Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 6
(Date:8/21/2014)...   Royal Philips (NYSE: ... received 510(k) clearance from the U.S. Food and ... for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through 3D ... pre-procedural, high-precision positioning to treat aortic stenosis ailments.  ... available as part of Philips IntelliSpace Portal ...
(Date:8/21/2014)... JOSE, Calif. , Aug. 21, 2014  SI-BONE, ... medical device company that pioneered the use of the ... (MIS) device indicated for fusion of the sacroiliac (SI) ... ) published an update to its Lumbar Fusion Medical ... SI joint fusion procedure.  The policy states that the ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
The GLU method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Lipase in human serum and plasma....
Medicine Products: